Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

For the quarter ended June 2026, Zai Lab Limited Unsponsored ADR (ZLAB) reported revenue of $106.31 million, down 3.3% over the same period last year. EPS came in at -$0.46, compared to -$0.37 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $106.33 million, representing a surprise of -0.01%. The company delivered an EPS surprise of +19.3%, with the consensus EPS estimate being -$0.57.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Zai Lab Limited performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Product Revenue- ZEJULA: $32.08 million versus the two-analyst average estimate of $32.29 million. The reported number represents a year-over-year change of -21.8%.
• Product Revenue- OPTUNE: $12.2 million versus the two-analyst average estimate of $12.6 million. The reported number represents a year-over-year change of -1.2%.
• Product Revenue- QINLOCK: $9.59 million versus the two-analyst average estimate of $8.59 million. The reported number represents a year-over-year change of +12.4%.
• Product Revenue- NUZYRA: $17.1 million compared to the $17.36 million average estimate based on two analysts. The reported number represents a change of +19.6% year over year.
• Collaboration revenue: $0.56 million versus the two-analyst average estimate of $-0.67 million.
• Product Revenue- XACDURO: $7.96 million versus the two-analyst average estimate of $9.24 million.
• Product Revenue- AUGTYRO: $2.21 million compared to the $1.84 million average estimate based on two analysts.
• Product Revenue, net: $105.75 million compared to the $106.99 million average estimate based on two analysts.
• Product Revenue- VYVGART: $23.87 million compared to the $21.49 million average estimate based on two analysts. The reported number represents a change of -9.9% year over year.

View all Key Company Metrics for Zai Lab Limited here>>>

Shares of Zai Lab Limited have returned -7% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research